Head and Neck Cancer Therapeutics Global Market Overview 2024 with Forecasts to 2030

DUBLIN–(BUSINESS WIRE)–The “Head and Neck Cancer Therapeutics – A Global Market Overview” report has been added to ResearchAndMarkets.com’s offering.

The global market for Head and Neck Cancer Therapeutics is estimated at US$1.7 billion in 2024 and is anticipated to post a CAGR of 9.4% during the 2024-2030 analysis period and stand at a projected US$3 billion by 2030.

This global report on Head and Neck Cancer Therapeutics analyzes the market based on drug class, treatment type, route of administration, and end-users. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and where the market is progressing.

The head and neck cancer market is primarily driven by increased research and development, which leads to the approval of new drugs, particularly for immunotherapy, targeted therapy, and chemotherapy. Healthcare providers are developing effective treatment options for several types of head and neck cancers, as evidenced by FDA approvals for drugs like Cetuximab and Docetaxel. Market growth is also driven by the rising incidence of HPV infections and increased consumption of alcohol and tobacco, which contribute to the prevalence of head and neck cancers.

Additionally, advancements in diagnostic techniques allow for earlier detection, thereby improving treatment outcomes and increasing demand. Nevertheless, the market faces challenges such as high treatment costs limiting access for low- and middle-income patients, as well as adverse side effects like neuropathy and fatigue. Treatment resistance, where cancer cells evade therapies, and lengthy regulatory approval processes further impede market growth.

Head and Neck Cancer Therapeutics Regional Market Analysis

In 2024, North America led the global head and neck cancer therapeutics market, holding an estimated 46.8% market share. Growth in this region is attributed to its advanced healthcare infrastructure, strong awareness of the disease, substantial investments in research and development, and favorable reimbursement policies. The region’s dominant position is supported by its robust healthcare system and the high incidence of head and neck cancer associated with tobacco, alcohol, and HPV.

Conversely, the Asia Pacific region is expected to witness substantial growth with a CAGR of 10.9% during the forecast period 2024-2030, driven by the increasing number of head and neck cancer cases due to alcohol and tobacco use, growing consumer awareness, and higher healthcare spending. Market expansion in this region is further stimulated by the improving healthcare infrastructure, aging population, and rising disposable incomes. Countries such as China and India are particularly affected by a high prevalence of cancer, influenced by lifestyle factors and government efforts to improve cancer care.

Head and Neck Cancer Therapeutics Market Analysis by Drug Class

Programmed Cell Death (PD) Inhibitors dominate the head and neck cancer therapeutics market with an estimated share of 42.1% in 2024 and is projected to be the fastest-growing therapeutic class, with a CAGR of 10.5% during the analysis period 2024-2030. These inhibitors have shown promising results in improving survival rates and extending progression-free survival, especially in patients with advanced or recurrent cancer. Due to their effectiveness, there is increasing demand for both monotherapy and combination treatments. Current clinical trials are focused on improving treatment approaches, identifying relevant biomarkers, and exploring new combinations.

Head and Neck Cancer Therapeutics Market Analysis by Treatment Type

Immunotherapy is the largest market in the head and neck cancer therapeutics market, holding a share of 43.6% in 2024, and is projected to record the fastest CAGR of 10.7% during the analysis period 2024-2030. By utilizing the body’s immune system to target cancer cells, immunotherapy presents promising treatment options for advanced or recurring head and neck cancers, with Pembrolizumab established as a primary therapy.

Growth in this sector is expected due to increased patient awareness and the active involvement of the FDA and EMA in approving new formulations. Targeted therapy held the second-largest market share at 22% in 2024, concentrating on specific molecular changes in tumors by interrupting critical signaling pathways. The active participation of companies and healthcare organizations further bolsters the expansion of targeted therapies.

Head and Neck Cancer Therapeutics Market Analysis by Route of Administration

The injectable segment dominated the head and neck cancer therapeutics market in 2024, with a 67.4% share. This dominance is attributed to the effectiveness of various cancer medications, such as chemotherapy and immunotherapy, administered intravenously or through injectables to ensure better absorption and efficacy. Injectable drugs like Cisplatin are notable for their controlled delivery and improved formulations, enhancing treatment efficacy.

Conversely, oral administration is anticipated to be the fastest-growing segment, with a CAGR of 10.4% during the forecast period 2024-2030, driven by advancements in oral chemotherapy formulations and patient preferences for convenient at-home treatment options. Oral medications provide flexible treatment schedules, reduce clinic visits, and contribute to personalized head and neck cancer treatment strategies, improving patients’ overall quality of life.

Head and Neck Cancer Therapeutics Market Analysis by End-User

In 2024, hospitals dominate the head and neck cancer therapeutics end-user market, holding an estimated share of 49.1% due to their well-equipped infrastructure and advanced disease diagnosis capabilities. On the other hand, the Ambulatory Surgical Centers (ASCs) segment is anticipated to register the fastest CAGR of 10.9% during the analysis period from 2024 to 2030, propelled by the increasing demand for cost-effective outpatient surgical treatments and technological progress enabling complex procedures in ASCs. Additionally, this growth is further driven by the rising prevalence of the disease and the necessity for faster treatment options.

Head and Neck Cancer Therapeutics Market Report Scope

Key Attributes:

Report Attribute Details
No. of Pages 301
Forecast Period 2024 – 2030
Estimated Market Value (USD) in 2024 $1.7 billion
Forecasted Market Value (USD) by 2030 $3 billion
Compound Annual Growth Rate 9.4%
Regions Covered Global

Key Global Players

  • AbbVie Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Head and Neck Cancer Therapeutics Market by Geographic Region

  • North America (The United States, Canada, and Mexico)
  • Europe (Germany, France, United Kingdom, Italy, Spain, and Rest of Europe)
  • Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
  • South America (Brazil, Argentina, and Rest of South America)
  • Rest of World

Head and Neck Cancer Therapeutics Market by Drug Class

  • Programmed Cell Death (PD) Inhibitors
  • Microtubule Inhibitors
  • Epidermal Growth Factor Receptor (EGFR) Inhibitors

Head and Neck Cancer Therapeutics Market by Treatment Type

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy
  • Surgery

Head and Neck Cancer Therapeutics Market by Route of Administration

  • Injectable
  • Oral

Head and Neck Cancer Therapeutics Market by End-User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers (ASCs)

For more information about this report visit https://www.researchandmarkets.com/r/iwl4td

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

*****************************************************************************************************

More info for healthcare startups : Healthcare Investors Database and Healthcare Investors Matchmaking .

World Anti-obesity Drugs Market Report 2024-2034: Top Anti-obesity Products, Pipeline Analysis by Phase, New Product Launches – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Anti-obesity Drugs Market Report 2024-2034” report has been added to ResearchAndMarkets.com’s offering.

Overall world revenue for Anti-obesity Drugs Market, 2024 to 2034 in terms of value the market, will surpass US$ 78.00 billion in 2034, the work calculates. The publisher predicts strong revenue growth through to 2034. The work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

The Anti-obesity Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increased Prevalence of Obesity

Over the past few decades, obesity rates have risen dramatically across all age groups and demographics, fuelled by a combination of genetic, environmental, socioeconomic, and cultural factors. The World Obesity Federation estimated that by 2020 around 770 million adults globally were affected by obesity, and that figure is anticipated to exceed one billion by 2030. Changes in dietary habits, sedentary lifestyles, urbanization, and globalization have contributed to the widespread adoption of unhealthy eating patterns and reduced physical activity levels, leading to excess weight gain and obesity-related health complications.

Moreover, obesity is not only a standalone health condition but also a major risk factor for numerous chronic diseases, including type 2 diabetes, cardiovascular diseases, certain cancers, and musculoskeletal disorders, further exacerbating its impact on population health. The consequences of obesity extend beyond individual health outcomes to encompass societal and economic burdens, including increased healthcare costs, lost productivity, and diminished quality of life.

Addressing the multifaceted drivers of obesity requires a comprehensive and multi-sectoral approach that encompasses policy interventions, community-based initiatives, education campaigns, and healthcare strategies aimed at promoting healthy lifestyles, improving access to nutritious foods, and creating supportive environments for physical activity. By tackling the root causes of obesity and implementing effective prevention and treatment measures, stakeholders can mitigate the escalating obesity epidemic and mitigate its far-reaching consequences on global health and well-being.

Rising Healthcare Expenditure

As obesity rates continue to climb globally, healthcare systems are increasingly allocating resources towards interventions aimed at combating this epidemic. This heightened expenditure encompasses various aspects, including research and development efforts to innovate new and more effective anti-obesity drugs, healthcare provider education and training on obesity management strategies, as well as patient outreach and support programs. Additionally, the economic burden of obesity-related health complications, such as diabetes, cardiovascular diseases, and certain cancers, further underscores the necessity of investing in preventive and therapeutic measures to mitigate these downstream health costs.

Furthermore, as healthcare systems transition towards value-based care models that prioritize preventive interventions and chronic disease management, there is a growing emphasis on the role of pharmacotherapy in comprehensive obesity treatment plans. While the upfront costs of anti-obesity drugs may seem significant, they are often outweighed by the potential long-term benefits of improved health outcomes and reduced healthcare expenditures associated with obesity-related comorbidities.

Overall, the rising healthcare expenditure in the anti-obesity drugs market reflects a strategic investment in addressing a pressing public health issue and underscores the importance of prioritizing obesity management within healthcare budgets to mitigate the broader societal and economic impacts of this epidemic.

Competitive Landscape

Key players within the Anti-obesity drugs market compete based on the diversity and efficacy of their product portfolios. Some focus on developing novel drugs with unique mechanisms of action, while others may specialize in repurposing existing medications for weight management. Innovation is a crucial driver of competition in the anti-obesity market.

Companies invest in research and development to discover new drug targets, formulations, and delivery methods that can offer improved outcomes for patients with obesity. Collaboration allows companies to pool their R&D efforts, share scientific insights, and access complementary technologies or expertise. This can expedite the discovery and development of novel anti-obesity medications.

Market Dynamics

Market Driving Factors

  • Increasing Prevalence of Obesity
  • Growing Awareness of Health Risks Associated with Obesity
  • Technological Advancements
  • Favourable Government Policies to Address Obesity Epidemic

Market Restraining Factors

  • Adverse Drugs Reactions Associated with Anti-obesity Drugs
  • Adherence to Weight Management Medications
  • Lack of Access to Affordable Anti-obesity Drugs

Market Opportunities

  • Increasing Number of Individuals Grappling with Obesity
  • Automation in Drug Development Technologies
  • Utilization of Digital Platforms to Enhance Patient Engagement

Anti-obesity Drugs Analysis

  • Top Anti-obesity Products, by Revenue
  • Pipeline Analysis by Phase
  • New Product Launches

COVID-19 Impact Analysis

Porter’s Five Forces Analysis

PEST Analysis

Leading companies profiled in the report

  • Arena Pharmaceuticals Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Carmot Therapeutics, Inc.
  • CHEPLAPHARM Arzneimittel GmbH
  • CohBar, Inc.
  • Curaxx Pharmaceuticals LLC
  • Eisai Co., Ltd.
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Hanmi Pharm Co., Ltd.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • VIVUS LLC
  • Zydus Lifesciences

Segments Covered in the Report

Drug Type

  • Prescription
  • OTC

Mechanism of Action

  • Glucagon like Peptide GLP-1 Agonists
  • Gastric inhibitory Polypeptide Receptor (GIPR) Antagonist
  • Amylin Receptor Agonist
  • Lipase Inhibitors
  • Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)
  • Others

Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous

Distribution channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

For more information about this report visit https://www.researchandmarkets.com/r/ggf329

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Immunotherapy Drugs Market Size & Market Analysis

The global immunotherapy drugs market size was valued at USD 110.55 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.92% from 2022 to 2030. The market is primarily driven by the rising incidence of chronic diseases globally, like diabetes. 

For instance, in March 2022, Nextera AS strategically collaborated with Zelluna Immunotherapy AS for the development of optimized TCRs for cancer immunotherapy. Furthermore, in February 2022, Biomunex Pharmaceuticals collaborated with Institut Curie for the development of an immunotherapy drug candidate for treating hematological malignancies using Biomunex Pharmaceuticals’ BiXAR technology. Moreover, in January 2021, Boehringer Ingelheim International GmbH signed a licensing agreement with Enara Bio for novel cancer immunotherapies by utilizing Enara Bio’s Dark Antigen discovery platform.

In addition, the high adoption of biosimilar drugs in immunotherapy is anticipated to boost growth in market dynamics. For instance, Abevmy, a biosimilar of Avastin, was launched by Biocon Biologics and Viatris Inc. in Canada across four oncology indications, in May 2022. Furthermore, the European Medicines Agency (EMA) accepted the Sandoz application for high concentration formulation of its biosimilar Hyrimoz (adalimumab) indicated for rheumatoid arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. These developments are expected to drive industry growth.

Conversely, high attrition rates and high costs associated with immunotherapy treatment are projected to impede industry growth. According to the American Society of Clinical Oncology, immunotherapy launched between 2009 and 2014 costs above USD 100,000 annually. Moreover, CAR T-cell therapy costs up to approximately USD 500,000 annually. In addition, as per the NCBI, anti-cancer drug prices are two times higher in the U.S. than in Europe.

North America dominated the global industry in 2021 and accounted for the largest share of more than 44.90% of the overall revenue. The launch and regulatory approval of new immunotherapy drugs and favorable reimbursement policies are projected to aid in the region’s growth. For instance, Keytruda, Merck’s anti-PD-1 therapy, was approved by the FDA in October 2021, in combination with chemotherapy for cervical cancer treatment. Moreover, in August 2021, Opdivo (nivolumab) manufactured by Bristol Myers Squibb Co. received FDA approval for the treatment of urothelial carcinoma.

The leading players are focusing on growth strategies, such as innovations in the existing products, approval of new products, and mergers & acquisitions, to gain higher market shares. For instance, in January 2021, Sanofi entered an agreement with Kymab to acquire the company for an upfront payment of about USD 1.1 billion, resulting in the addition of KY1005, a monoclonal antibody, into its pipeline. Some of the prominent players in the global immunotherapy drugs market include:

  • Amgen, Inc.
  • Novartis AG
  • AbbVie, Inc.
  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services, Inc.
  • AstraZeneca
  • GSK
  • Sanofi
  • Bayer AG

On the basis of drug types, the industry has been further categorized into cancer, autoimmune diseases, infectious diseases, and others. The cancer segment accounted for the largest revenue share of more than 91.10% in 2021 owing to the increased prevalence of cancer, coupled with a rise in the launch of cancer immunotherapies. As per Globocan 2020, breast cancer and lung cancer are the two most predominant cancers with a prevalence of approximately 11.7% and 11.4%. Moreover, in April 2021, the FDA approved Opdivo (nivolumab) in combination with chemotherapy for patients with gastric cancer.

On the other hand, the autoimmune diseases segment is anticipated to register the fastest growth rate during the forecast period. The growth of this segment can be attributed to the increasing cases of autoimmune diseases across the globe and regional approvals of immunotherapy drugs. As per NCBI research, the estimated global prevalence of rheumatoid arthritis is around 0.46% of the global population. Moreover, GSK’s Benlysta (belimumab) received China’s National Medical Products Administration approval for the treatment of active lupus nephritis in February 2022.

Source : https://www.grandviewresearch.com/industry-analysis/immunotherapy-drugs-market-report

Cancer Immunotherapy Market Size & Market Analysis

The global cancer immunotherapy market was valued at USD 104.96 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.2% from 2022 to 2030. Increasing prevalence of oncology across the globe coupled with a surge in R&D efforts for the development of novel oncology therapeutics are the major driving factors for the market. Moreover, the presence of various organizations that support immunotherapy research is also expected to fuel market growth. The most common type of malignancies affecting the U.S. population is breast, prostate, lung, and colorectal. In addition, according to the Cancer Council, Australia reported 150,000  new cancer cases with 50,000 deaths in 2020. Thus, the surge in prevalence of malignant tumor cases is anticipated to accelerate market expansion in the coming years.

The presence of various government and non-government organizations that create awareness and promote research is augmenting market expansion. For instance, Cancer Research Institute funded more than 120 clinical trials and invested around USD 474 million in research. Moreover, the Society for Immunotherapy of Cancer(SITC) is engaged in improving patient outcomes by advancing the science and application of oncology immunotherapy. These organizations are working with scientists and researchers to discover novel treatment regimens of immune therapy.

Cancer Immunotherapy Market Size & Market Analysis

Furthermore, increasing funding for the development of novel treatments is expected to boost R&D activities to develop cancer immunotherapy. For instance, in June 2022, a group of Stanford scientists received funding of USD 13 million from Cancer Grand Challenges, a funding initiative by Cancer Research UK and the U.S. National Cancer Institute. This funding is awarded for the development of next-generation immunotherapies, the study of extrachromosomal DNA, and the investigation of early-stage malignancies.

Increasing approval of novel immunotherapies is anticipated to propel the market growth over the forecast period. During 2020-2022, the U.S. FDA has approved various anti-PD-1/L1 antibodies such as nivolumab, atezolizumab, avelumab, dostarlimab, and others for the treatment of NSCLC, renal cell carcinoma, melanoma, breast, prostate malignancies, and others. The higher approvals of immunotherapeutic agents have propelled the market growth.

Various Strategic initiatives undertaken by leading players are also expected to facilitate the market demand. For instance, in August 2022,  BioNTech SE and Genmab A/S expanded their strategic collaboration for the development and launch of new immune therapies for the treatment of various cancer forms. Moreover, in March 2022,  Merck & Co., Inc announced the approval of KEYTRUDA from the U.S. FDA. KEYTRUDA is an anti-PD-1 therapy for the treatment of advanced endometrial carcinoma.

However, side effects associated with immunotherapy are likely to hamper the prescription rate for cancer treatment. The available therapies are associated with several adverse effects, such as pain, insomnia, fatigue, nausea, and gastrointestinal conditions. These adverse effects impact the overall quality of life of patients and the management of these adverse effects incurs extra costs. In addition, prolonged consumption of immunotherapeutic drugs may cause severe damage to the organs and increase the incidence of organ failure cases.

The presence of various government and non-government organizations that create awareness and promote research is augmenting market expansion. For instance, Cancer Research Institute funded more than 120 clinical trials and invested around USD 474 million in research. Moreover, the Society for Immunotherapy of Cancer(SITC) is engaged in improving patient outcomes by advancing the science and application of oncology immunotherapy. These organizations are working with scientists and researchers to discover novel treatment regimens of immune therapy.

Cancer Immunotherapy Market Size & Market Analysis

Furthermore, increasing funding for the development of novel treatments is expected to boost R&D activities to develop cancer immunotherapy. For instance, in June 2022, a group of Stanford scientists received funding of USD 13 million from Cancer Grand Challenges, a funding initiative by Cancer Research UK and the U.S. National Cancer Institute. This funding is awarded for the development of next-generation immunotherapies, the study of extrachromosomal DNA, and the investigation of early-stage malignancies.

Increasing approval of novel immunotherapies is anticipated to propel the market growth over the forecast period. During 2020-2022, the U.S. FDA has approved various anti-PD-1/L1 antibodies such as nivolumab, atezolizumab, avelumab, dostarlimab, and others for the treatment of NSCLC, renal cell carcinoma, melanoma, breast, prostate malignancies, and others. The higher approvals of immunotherapeutic agents have propelled the market growth.

Various Strategic initiatives undertaken by leading players are also expected to facilitate the market demand. For instance, in August 2022,  BioNTech SE and Genmab A/S expanded their strategic collaboration for the development and launch of new immune therapies for the treatment of various cancer forms. Moreover, in March 2022,  Merck & Co., Inc announced the approval of KEYTRUDA from the U.S. FDA. KEYTRUDA is an anti-PD-1 therapy for the treatment of advanced endometrial carcinoma.

However, side effects associated with immunotherapy are likely to hamper the prescription rate for cancer treatment. The available therapies are associated with several adverse effects, such as pain, insomnia, fatigue, nausea, and gastrointestinal conditions. These adverse effects impact the overall quality of life of patients and the management of these adverse effects incurs extra costs. In addition, prolonged consumption of immunotherapeutic drugs may cause severe damage to the organs and increase the incidence of organ failure cases.

The lung cancer segment dominated the market in 2021. The rising prevalence of lung malignancies, increasing adoption of immunotherapy, increase in awareness programs, and presence of a robust pipeline of investigational candidates are some of the key factors expected to drive the segment’s growth. Furthermore, rising product approval and product launch fueling the demand forward. For instance, in October 2021, the U.S. FDA approved Tecentriq (atezolizumab) for the treatment of stage II and stage III NSCLC.

The breast cancer segment held the second largest share owing to the high prevalence of the disease, ongoing research activities, and rising investments by leading players to develop novel therapeutics for breast malignancies are expected to accelerate segment expansion. However, the prostate cancer segment is anticipated to experience the fastest growth rate over the forecast period.

Market players are adopting strategies such as new product development, merger & acquisition, and partnership to increase their market share. For instance, in February 2022, Medigene AG and BioNTech SE collaborated to develop T-cell receptor-based immunotherapies for oncology disorders. Some prominent players in the cancer immunotherapy market include:

  • Pfizer Inc.
  • AstraZeneca
  • Merck & Co., Inc
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Genentech, Inc (Roche)
  • Novartis AG
  • Lilly
  • Johnson & Johnson Services, Inc
  • Immunocore, Ltd

In 2021, North America led the overall market in terms of revenue due to the presence of a large number of leading players coupled with various Strategic initiatives undertaken by them. Moreover, the increase in disease prevalence and the presence of various government and non-government organizations that promote research activities for cancer immunotherapy, and the increasing approval of novel drugs are fueling the regional market growth. For instance, in April 2022, the U.S. FDA approved Opdivo (nivolumab) for the treatment of NSCLC in adult patients. Asia Pacific is projected to witness the fastest growth rate over the forecast period. The increase in the geriatric population, a large patient base of a targeted diseases, and improving healthcare infrastructure are some of the primary factors driving the growth. Moreover, the rising regulatory approvals of immune therapies in the region are also contributing region’s expansion. For instance, during 2020-2022, the National Medical Products Administration of China approved Pembrolizumab and Durvalumab for the treatment of esophageal cancer and SCLC.

Source : https://www.grandviewresearch.com/industry-analysis/cancer-immunotherapy-market

mRNA Therapeutics Market Size & Market Analysis

The global mRNA therapeutics market size is expected to reach USD 37.76 billion by 2030. It is expected to expand at a CAGR of 1.7% from 2022 to 2030. One of the main factors propelling the market growth is the rising incidence of chronic and infectious diseases like diabetes, HIV, cancer, and CVDs.

mRNA therapeutics Market Size & Market Analysis

The growing need for therapeutic drugs and vaccinations to combat viral illnesses like Ebola, influenza, HIV, and most recently COVID-19 is expected to fuel industry growth. The COVID-19 virus has been the focus of numerous government organizations and vaccine producers, and it is anticipated that this will accelerate market expansion.

mRNA therapeutics Market Size & Market Analysis

Furthermore, the availability of vaccination doses around the world is projected to increase during the forecast period as a result of multiple suppliers using novel techniques, such as combining the phase 1 and phase 2 clinical trial stages and obtaining regulatory clearances more quickly from health agencies, thus contributing to the industry growth. With the use of cutting-edge technologies, mRNA vaccines and therapeutics are generated in comparison to conventional medications. These products are less expensive to produce, more powerful against infections, and have enhanced immunogenicity. A favourable outlook for market expansion is also being created by advancements in the compositions of lipid nanoparticles for in-vivo systemic delivery of mRNA.
For instance, in March 2022, The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) launched a phase 1 clinical trial to assess three potential HIV vaccines using a messenger RNA (mRNA) platform due to its active component and direct the cells to make a protein (or perhaps a protein fragment) that stimulates an immune response using artificial mRNA created in a lab, which enhances the vaccine with more specificity as well as robust stability. Thus, it will increase the demand and further boost the industry growth.
As another significant growth-inducing element, pharmaceutical firms are spending on mRNA technology since they can combine numerous molecules into a therapeutic drug. The market is expected to be driven by additional factors, such as significant biotechnology-related research and development (R&D) initiatives and advancements in medical technology. For instance, Moderna and AstraZeneca are working together on a myocardial ischemia therapy using mRNA (a form of cardiac disease that develops when there is a decrease in blood flow to the heart, depriving the heart muscle of necessary oxygen). Similarly, mRNA treatments for heart disease are also being tested by Arcturus Therapeutics. Such investments are likely to supplement the market growth in the coming years.

mRNA therapeutics Market Size & Market Analysis

The COVID-19 pandemic is anticipated to positively impact the industry growth. The COVID-19 vaccine is one of the diseases for which the mRNA technology is being used. In addition to its predominant use in cancer or metastasis cancer therapy, the COVID-19 vaccine is the main factor driving the market for mRNA. The mRNA firms are working hard to create COVID-19 vaccines for the next generation due to the coronavirus mutation and the potential spread of virus variants. For instance, in June 2022, The Food and Drug Administration approved the Moderna COVID-19 Vaccine and also the Pfizer & BioNTech COVID-19 Vaccine for use in children as young as 6 months old as COVID-19 preventative measures. As a result, the usage of these technologies is projected to increase during the COVID-19 pandemic and result in industry growth.
Additionally, there has been a discernible trend toward consolidation over the past few years, with players forming strategic alliances to support current R&D projects. For instance, in February 2021, building on their current partnership, GlaxoSmithKline plc and CureVac N.V. announced a new USD152.36 million agreement to create COVID-19 next-generation mRNA vaccines with the possibility for a multi-valent strategy to address numerous developing variations in a single vaccination. As additional mRNA-based therapeutic / vaccine leads exhibit proof-of-concept, go through clinical testing, and eventually hit the market, the opportunity for stakeholders involved in this specialized industry segment is likely to experience a significant increase in the predicted future.

List of main Players in the mRNA Therapeutics Market Size & Market Analysis :

Moderna, Inc.
BioNTech SE
CureVac N.V.
Arcturus Therapeutics
Translate Bio, Inc.
GSK plc.
Argos Therapeutics Inc.
Sangamo Therapeutics, Inc.
Pfizer Inc.
AstraZeneca plc.
CRISPR Therapeutics AG

Source : https://www.researchandmarkets.com/reports/5644939/global-mrna-therapeutics-market-size-share-and#:~:text=The%20global%20mRNA%20therapeutics%20market%20size%20is%20expected,infectious%20diseases%20like%20diabetes%2C%20HIV%2C%20cancer%2C%20and%20CVDs.

Metastasis Cancer Treatment Market size & Market Analysis

The global Metastasis Cancer Treatment Market size in terms of revenue was worth of $63.18 Billion in 2020 and is expected to reach $161.67 Billion in 2027, growing at CAGR of 12.3% from 2021 to 2027.

Metastasis Cancer Treatment Market size & Market Analysis

Metastasis cancer represents the advanced form of cancer, which occurs when the cancer cells start spreading from the site of origin to different parts of the body. Treatment for Metastasis cancer aims to slow the expansion or spread of the cancer. Treatment depends on the sort of cancer, where it started, the dimension and location of the metastasis and other factors. The treatment for Metastasis cancer is often different from the ones used for a normal tumor. Treatment of Metastasis cancer is often not curable and is mainly focused on providing relaxing care. Several manufactures are investing in oncology market and are making vigorous efforts for the supply of cost-effective cancer treatment drugs used in chemotherapy, radiation therapy and hormone therapy. Patients all over the world are looking forward for advanced cancer therapy drugs to capture their condition, which is turn, is increasing the adoption rate of the Metastasis cancer treatment drugs.

Metastasis occurs when cancer progresses to different parts of the body from where it originated and it is the culmination of neoplastic progression. Cancer metastasis is a major challenge in cancer treatment as it is difficult to diagnose and treat. Metastasis accounts for 90% of cancer associated mortality and only a small number of patients with metastatic cancer can be treated with conventional strategies such as chemotherapy, radiotherapy and surgical removal.

Metastasis Cancer Treatment Market size & Market Analysis

Increasing focus on development of new strategies to prevent metastasis, rapid adoption of stem cells and oncolytic viruses to treat metastatic cancer, and growing caseload of cancer across the globe are some key factors expected to drive market revenue growth over the forecast period. In addition, increasing research and development activities to understand molecular mechanisms of metastasis and rising number of clinical trials to develop personalized treatments that can specifically target metastases are some other key factors expected to contribute revenue growth of the market going ahead.

The major drivers for the global Metastasis cancer treatment market growth are rising prevalence of cancer and high medical needs of patients who have Metastasis cancer. Rising prevalence of Metastasis cancer is one of the major factors expected to drive the growth of the global Metastasis cancer treatment market. It is estimated that metastasis is responsible for about 90% of cancer deaths. This estimate has changed little in more than 50 years, according to National Center for Biotechnology Information. The increasing cancer burden is due to several factors, including population growth and ageing as well as the changing prevalence of certain causes of cancer linked to social and economic development. Breast cancer is the second most common cause of death from cancer in 6% women. It is estimated that 42,690 people will die from breast cancer, according to American Society of Clinical Oncology. Metastasis breast cancer will cause the vast majority of those deaths. However, high cost of Metastasis cancer treatment may hamper the growth of this market. In spite of that, increasing number of pharmaceutical, biotechnology and diagnostic companies are focusing on research and development of innovative oncology medicines to provide advanced treatment which may create more opportunities for the further growth of the market.

Metastasis Cancer Treatment Market size & Market Analysis

Metastasis is the major reason for treatment failure in cancer patients and accounts for majority of cancer-related deaths. Metastasis also causes treatment failure even in tumors that are sensitive to chemotherapy or radiotherapy. Metastatic tumors are difficult to treat with conventional therapy due to their anatomically diffuse localization and resistance to cytotoxic agents. Rapid technological advancements in imaging and cancer cell identification have significantly improved understanding of cancer metastasis. Treatment of metastatic cancer primarily aims to slow the growth or spread of cancer and typically requires systemic therapy or oral or intravenous medications to reach cancer cells throughout the body.

Other treatment approaches include immunotherapy, radiation therapy, surgical intervention, or a combination of these treatments. In addition, clinical trials offer access top novel treatment approaches that can prove to be more appropriate and effective as compared to standard of care options. Various therapeutic options are available to ease side effects and enhance quality of life of patients even after metastatic cancer has stopped responding to treatments. Development of new strategies to manage and treat metastatic cancer and advancements in stem cell therapy are some factors expected to drive market revenue growth over the forecast period.

However, difficulties associated with the treatment of metastatic cancer, high costs of cancer treatment, and resistance of metastatic cells to conventional treatment approaches and cytotoxic agents are some key factors expected to restrain market growth to a certain extent over the forecast period. In addition, lack of knowledge regarding metastatic processes, recurrence of cancer, and systemic side effects of treatment are some other factors expected to hamper market growth to a certain extent over the forecast period.  

North America is the highest revenue generating market for Metastasis cancer treatment solutions. The rate of diagnosis is high in this region due to advances healthcare infrastructure and awareness among the people. According to American cancer society; in 2016; there were approximately 3.5 million women living with an antiquity of breast cancer in the United States. More than 16.9 million Americans with a history of cancer were alive on January 1st, 2019, and this number is projected to grow to more than 22.1 million by January 1st, 2030, according to Carevive Systems, Inc. Europe is second largest region for this market due to rising Advancements in immune-oncology and precision medicine. Immense scientific innovation in the field of oncology has resulted in higher regulatory approval rates of cancer treatment drugs used in chemotherapy, radiation therapy, and hormone therapy, among others in this region. In 2017, more than 3,500 radiation therapy machines were used by hospitals and providers of ambulatory health care in the European Union (EU). The performance of breast-protection surgery has increased, and the use of neoadjuvant therapy to downstage locally advanced breast cancer has become more common in the Asia–Pacific region.

Metastasis Cancer Treatment – Main Players :

List of main players in the Global Metastasis Cancer Treatment Market size & Market Analysis :

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • BRISTOL-MYERS SQUIBB COMPANY
  • Eli-Lilly and Company
  • Hoffmann-La Roche AG
  • JOHNSON & JOHNSON
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • SANOFI

Source Metastasis Cancer Treatment Market size & Market Analysis : https://brandessenceresearch.com/healthcare/metastasis-cancer-treatment-market

Liposome Drug Delivery Market Size & Market Analysis

The global liposome drug delivery market is anticipated to grow with a CAGR of 10.69% over the forecast period, 2022 – 2031. The market is estimated to garner a revenue of near to USD 11980 Million by the end of 2031, up from a revenue of more than USD 4350 Million in the year 2021.

The liposomal doxorubicin segment, by the end of 2031, is projected to garner the largest revenue of about USD 3220 Million. Additionally, in the year 2021, the segment generated a revenue of near to USD 1140 Million. The market in North America, by the end of 2031, is projected to garner the largest revenue of close to USD 4430 Million. Additionally, in the year 2021, the market in the region generated a revenue of around USD 1690 Million.

Liposome Drug Delivery Market Size & Market Analysis

The global liposome drug delivery market is anticipated to grow with a CAGR of 10.69% over the forecast period, 2022 – 2031. Factors such as the surge in concern for the rising prevalence of cancer around the globe, along with the increasing adoption of advanced drug delivery systems for the treatment of the disease are anticipated to drive the growth of the market in the coming years.

Additionally, factors such as the surge in use of liposomes as drug delivery systems, and the numerous benefits associated with the use of liposomes for drug delivery in cancer treatment are also projected to boost the market growth during the forecast period. The market is estimated to garner a revenue of near to USD 11980 Million by the end of 2031, up from a revenue of more than USD 4350 Million in the year 2021.

Liposomal Drug Delivery Market Size & Market Analysis

The global liposome drug delivery market is segmented by numerous segments, which include segmentation by product, technology, application, and by region. By product, the market is segmented by product into liposomal doxorubicin, liposomal paclitaxel, liposomal amphotericin B, and others. The liposomal doxorubicin segment, by the end of 2031, is projected to garner the largest revenue of about USD 3220 Million. Additionally, in the year 2021, the segment generated a revenue of near to USD 1140 Million.

On the basis of regional analysis, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America, by the end of 2031, is projected to garner the largest revenue of close to USD 4430 Million. Additionally, in the year 2021, the market in the region generated a revenue of around USD 1690 Million.

Major players in the Liposome Drug Delivery Market Size & Market Analysis :

  • Spectrum Pharmaceuticals Inc.
  • Gilead Sciences Inc.
  • Celsion Corporation
  • Ipsen Pharma
  • Pacira Pharmaceuticals Inc.
  • Novartis AG
  • CordenPharma International
  • FUJIFILM Toyama Chemical Co. Ltd.
  • Takeda Pharmaceutical Company Limited
  • Johnson & Johnson Services Inc.
  • Astellas Pharma Inc.
  • Elan Pharmaceuticals (Perrigo Company plc)
  • Merrimack Pharmaceuticals Inc.
  • Janssen Pharmaceuticals Inc.

Liposome Drug Delivery Market Size & Market Analysis

Source : https://www.researchandmarkets.com/reports/5624580/global-liposome-drug-delivery-market-analysis

Bladder Cancer Drugs Market size & Market analysis

The global bladder cancer drugs market is expected to grow from $1.98 billion in 2021 to $2.35 billion in 2022 at a compound annual growth rate (CAGR) of 19.1%. The market is expected to reach $4.45 billion in 2026 at a CAGR of 17.3%.

Bladder Cancer Drugs Market size & Market analysis

North America is the largest region in the bladder cancer drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The American Cancer Society’s estimates for bladder cancer in the United States for 2021 are about 83,730 new cases of bladder cancer. In addition, the rising geriatric population, unhygienic sedentary lifestyle, and smoking habits are increasing the prevalence of most cancer cases.

When the cells that make up the urinary bladder begin to proliferate out of control, bladder cancer develops. More cancer cells can form a tumor and spread to other places of the body as time goes on. The bladder wall is made up of multiple layers. Each layer is made up of many cell types. The urothelium or transitional epithelium, which lines the inside of the bladder, is where most bladder malignancies begin. Cancer progresses to a higher stage, gets more advanced, and is more difficult to cure when it spreads into or through the other layers of the bladder wall. Cancer may spread outside the bladder and into neighboring structures over time. It could spread to nearby lymph nodes or other organs.

Bladder Cancer Drugs Market size & Market analysis

The most frequent type of bladder cancer is urothelial carcinoma, also known as transitional cell carcinoma (TCC). Urothelial carcinoma is virtually always been the cause of bladder cancer. Squamous cell carcinomas account for about 1% to 2% of bladder malignancies in the United States. The cells, when viewed under a microscope, resemble the flat cells present on the skin’s surface. Squamous cell carcinomas of the bladder are almost always invasive. Adenocarcinomas make up roughly 1% of all bladder cancers. These cancer cells have a lot in common with colon cancer gland-forming cells. Almost of bladder adenocarcinomas are invasive. Small-cell carcinomas account for less than 1% of bladder cancers. They begin in neuroendocrine cells, which are nerve-like cells. These cancers grow quickly and require chemotherapy, similar to that used to treat small cell carcinoma of the lung. Sarcomas begin in the bladder’s muscle cells, but they are extremely rare. Soft Tissue Sarcoma and Rhabdomyosarcoma have more information. These less common kinds of bladder cancer (apart from sarcoma) are treated similarly to TCCs, especially in the early stages, but alternative drugs may be used if chemotherapy is required.

Major organizations are investing on the research to utilize nano-technology as a means to deliver drugs into the human body. nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale.

This method of delivery helps doctors to offer a simple and effective way of treating bladder cancer in their patients, due to the fact that the nanoparticles used in the treatment can attack the cancerous cells directly without harming the surrounding cells.

Bladder Cancer Drugs Market size & Market analysis

Source : https://www.researchandmarkets.com/reports/5559826/bladder-cancer-drugs-global-market-report-2022

Coronavirus Covid19 Covid-19 Diagnostics Market Size & Market Analysis

The global COVID-19 diagnostics market size was valued at USD 97.4 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 7.7% from 2022 to 2030. The market is driven by the rising government initiatives targeted toward the implementation of mass testing.

Coronavirus Covid19 Covid-19 Diagnostics Market Size & Market Analysis

Transitioning focus of new entrants toward at-home testing and integration of advanced software has been witnessed in the past few months. This is expected to increase patient convenience in regard to time-consuming laboratory-based testing. 

The considerable increase in patient population around the world, the enormous need for speedy diagnostics, and the lack of specific drug or vaccination are the primary factors driving the market for Covid-19 diagnostics. However, a lack of awareness among developing countries about the precautions that must be taken, as well as a scarcity of diagnostic kits and medical professionals with sufficient understanding about the use of diagnostic kits for new Covid-19, are expected to stymie market expansion. Leading diagnostic kit producers, on the other hand, can benefit from a number of profitable ventures by manufacturing rapid diagnostic kits. Moreover, several local players and small startups are producing diagnostic kits and assays to take advantage of huge prospects. For example, once the National Institute of Virology confirmed its test, Mylab, India gained permission from the Drug Controller of India for manufacturing the Covid-19 diagnostic kit.

Coronavirus Covid19 Covid-19 Diagnostics Market Size & Market Analysis

The demand for COVID-19 diagnostic products is set to propel further with the increasing number of coronavirus-infected patients, particularly post the ease of lockdown across the globe. According to World meter, the total number of cases witnessed a spike with 33,556,252 patients testing positive as of 28th September 2020 to 55,961,380 patients on 17th November 2020. Despite the gradual decline expected in the number of positive patients in 2021, integration of COVID-19 tests in routine diagnostic protocols is expected to maintain the growth of the market for Covid-19 diagnostics.

Moreover, these testing programs are set to pave way for the travel industry to gear up, creating a favorable environment for the entities operating in the market for Covid-19 diagnostics. The tourism and travel industries have been most affected during this pandemic outbreak, which has led to an upsurge in COVID-19 testing initiatives post August 2020, particularly in tourism-based countries and regions. This is also expected to propel the PoC testing market penetration as these tests are able to overcome the limitations associated with traditional testing.

Complex and pure reagents, such as probes, enzymes, and primers, are crucial in conducting tests in clinical laboratories. A number of factors like a sudden increase in demand, export bans, and stockpiling have led to the shortage of these reagents. Additionally, these reagents are manufactured by limited companies, therefore leading to a shortage of supply due to insufficient production capacity. The inadequate demand-to-supply ratio of reagents worldwide is anticipated to negatively impact the overall diagnosis rate and hinder the growth of the market for Covid-19 diagnostics.

The market for Covid-19 diagnostics is divided into two segments based on technology: PCR and immunoassay. Because of the rising need for coronavirus patient diagnosis, the PCR segment is likely to rise rapidly in the near future. Furthermore, PCR is regarded as the gold standard for detecting COVID-19 infections. The immunoassay segment is expected to increase at the fastest rate throughout the forecast period, due to a rise in the need for quick serological testing for disease diagnosis. A plethora of serological kits is being developed to confirm Sars Cov 2 infections.

The services segment is estimated to dominate the market for Covid-19 diagnostics and accounted for revenue share of 47.8% in 2021. Service providers are boosting their testing capabilities by expanding technological footprints in existing labs and diagnostic centers as well as by launching new, high-capacity laboratories, which has contributed to the segment growth. Collaborations between governments, test developers, public health organizations, and private laboratories accelerate the expansion of testing capacities. 

The reagents and kits segment is expected to register a CAGR of (7.2%) from 2020 to 2030. The reduction in the number of active COVID-19 cases is responsible for the declining market growth of this segment. In response to the pandemic, companies are implementing various strategic initiatives, such as new product development and collaborations.

Coronavirus Covid19 Covid-19 Diagnostics Market Size & Market Analysis

Source : https://www.grandviewresearch.com/industry-analysis/covid-19-diagnostics-market

Coronavirus Covid19 Covid-19 Treatments Drugs Market Size & Market Analysis

The global COVID-19 Therapeutics market size was valued at US$ 10.2 Billion in 2021, and it is expected to reach US$ 25.6 Billion in 2030, record a promising CAGR of 10.7% from 2021 to 2030.

Coronavirus Covid19 Covid-19 Treatments Drugs Market Size & Market Analysis

COVID-19 is a contagious disease triggered by the most recently discovered coronavirus, which has affected millions of individuals worldwide. The coronavirus can be treated with various drugs, including corticosteroids, antivirals, monoclonal antibodies, and kinase inhibitors. In August 2021, The World Health Organization (WHO) released a report that represents Artesunate, imatinib, and infliximab are three new potential medications being investigated in the latest phase of the global Solidarity clinical trials to find effective COVID-19 therapies. Additional medicines approved for emergency use include Eli Lilly and Company’s monoclonal antibodies bamlanivimab with etesevimab; Regeneron’s casirivimab and imdevimab; GlaxoSmithKline/Vir Biotechology’s Xevudy (sotrovimab); Roche’s Actemra; Celltrion’s Regkirona; and convalescent plasma. The growth of the COVID-19 Therapeutics Market is primarily attributed the increased prevalence of COVID-19 across the globe. In the first week of January 2022, Covid-19 cases have now been recorded in over 300 million people worldwide. The United States had over 50 million confirmed cases and over 800,000 deaths, making it the Country with the highest death toll. Pharmaceutical companies are investing heavily in product research due to the rising pandemic effect, and they are focusing on the production of enhanced therapeutics that can cure the covid-19. The market is further supported by rising awareness about coronavirus and collective efforts by the pharmaceutical companies and government in the development of covid-19 therapeutic drugs.

Coronavirus Covid19 Covid-19 Treatments Drugs Market Size & Market Analysis

The prominent players in the COVID-19 Therapeutics industry include Atea Pharmaceuticals, Inc., Fulcrum Therapeutics, CytoDyn, Eli Lilly and Company, Celltrion, Shanghai Junshi Biosciences Co., Ltd., NRX Pharmaceuticals, Veru Inc., Catalent, Inc., Humanigen, Inc., Molecular Partners AG, Cipla Limited, Merck, Regeneron Pharmaceuticals, Inc., Novartis International AG, Vir Biotechnology, Brii Biosciences Limited, Revive Therapeutics Ltd., GlaxoSmithKline plc, APEIRON Biologics AG, Janssen Pharmaceuticals, Bristol Myers Squibb, Trevena Inc, Constant Therapeutics LLC, Ono Pharmaceutical Co., Ltd., Amarin Corporation plc, NeuroBo Pharmaceuticals, Inc., FUJIFILM Toyama Chemical Co., Ltd., Innovation Pharmaceuticals Inc., Bellerophon Therapeutics, Sorrento Therapeutics, PhaseBio, BioAegis Therapeutics, Pfizer, Takeda, Roivant Sciences, Celltex Therapeutics, Blade Therapeutics, A.I. Therapeutics, Inc., Marinomed Biotech AG, Synairgen, Romark Laboratories, SAb Biotherapeutics, Kiniksa Pharmaceuticals, UNION therapeutics A/S, etc.

COVID-19 Therapeutics Market Regional Analysis

In 2021, North America is expected to have the largest share of R&D in the global covid-19 therapeutics market, owing to increased government spending on drug development, growing government initiatives for covid-19 vaccine R&D, an increasing number of market players, and the implementation of favorable government initiatives in the U.S. and Canada. However, due to increased government initiatives to increase medication production and the number of research and development activities, the Asia Pacific area is predicted to grow rapidly in the target market. In June 2021, India’s pharma regulator approved the emergency use of Eli Lilly and Company India’s antibody medication combination, which is used to treat mild to moderate COVID-19 patients. The monoclonal antibody medications bamlanivimab 700 mg, and etesevimab 1400 mg have been approved by the company. Both of these medicines are utilized to treat COVID-19 patients who have mild to moderate symptoms.

The Global COVID-19 therapeutics Market Segments : Antiviral , Monoclonal Antibodies, Glucocorticoid, Anticoagulant, Nitric oxide and Other Drug Class.

Coronavirus Covid19 Covid-19 Treatments Drugs Market Size & Market Analysis

Source : https://www.bloomberg.com/press-releases/2022-01-18/global-covid-19-therapeutics-market-worth-14-6-billion-by-2022-exclusive-report-by-insightace-analytic and https://www.insightaceanalytic.com/report/global-covid-19-therapeutics-market/1184